We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SIKA:SIXSika AG Analysis

Data as of 2026-05-23 - not real-time

CHF 147.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Sika AG is trading at CHF 147, just above its 20‑day SMA of 143.0 and 50‑day SMA of 139.6, indicating short‑term momentum but a neutral overall trend. The MACD histogram has turned positive (0.0003) and the signal line is bullish, while the RSI sits at 58.6, suggesting modest buying pressure without overbought conditions. Volume is on an increasing trend and the stock’s beta of 0.32 points to low market‑risk sensitivity, though 30‑day volatility is elevated at 34%. Market sentiment is at an "Extreme Greed" level (91.6 on the Fear & Greed Index), which may be pushing the price toward the resistance zone near CHF 150.2.
Fundamentally, the share appears overvalued as the DCF fair value is only CHF 65.6, far below the current price, and revenue has contracted by 7.9% YoY. Nonetheless, the company maintains a solid dividend yield of 2.5% with a payout ratio around 55%, and cash flow generation remains healthy despite a debt‑to‑equity of 83%. Analysts collectively rate the stock as a Buy with a median target of CHF 178, implying about a 22% upside from today’s level.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near short‑term support and SMA levels
  • Bullish MACD crossover with modest RSI
  • Increasing volume and low beta limiting downside

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Target price median of CHF 178 suggests ~22% upside
  • Stable dividend yield and sustainable payout ratio
  • Improving sentiment and technical momentum

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Revenue decline and high debt raise valuation concerns
  • Strong market position in specialty chemicals
  • Consistent cash flow supporting dividend continuity

Key Metrics & Analysis

Financial Health

Revenue Growth-7.90%
Profit Margin9.32%
P/E Ratio22.6
ROE15.25%
ROA6.10%
Debt/Equity83.13
P/B Ratio3.5
Op. Cash FlowCHF1.7B
Free Cash FlowCHF1.2B

Technical Analysis

TrendNeutral
RSI58.6
SupportCHF 134.90
ResistanceCHF 150.20
MA 20CHF 143.02
MA 50CHF 139.57
MA 200CHF 159.50
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61

Valuation

Fair ValueCHF 65.59
Target PriceCHF 179.69
Upside/Downside22.23%
GradeOvervalued
TypeValue
Dividend Yield2.52%

Risk Assessment

Beta0.32
Volatility34.37%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.